Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
QTTB
QTTB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
QTTB News
Q32 Bio Transfers ADX-097, a Complement Inhibitor, to Akebia Therapeutics
Dec 02 2025
NASDAQ.COM
Crude Oil Rises More Than 1%; November Sees Decline in ISM Manufacturing PMI
Dec 01 2025
Benzinga
Dow Falls 200 Points; Q32 Bio Stock Soars
Dec 01 2025
Benzinga
What’s Driving the Surge in Small-Cap Q32 Bio Stock This Monday?
Dec 01 2025
Benzinga
Q32 Bio Sells ADX-097 for $12M, Extends Cash Runway into 2027
Dec 01 2025
PRnewswire
Akebia Acquires Q32 Bio's Next-Gen Kidney Disease Treatment
Dec 01 2025
Newsfilter
Q32 Bio Transfers Phase 2 Complement Inhibitor ADX-097 to Akebia Therapeutics
Dec 01 2025
NASDAQ.COM
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Nov 13 2025
PRnewswire
Healthcare Rally: Pulmonx, UHS, and X4 Experience After-Hours Gains Following Strategic Announcements
Oct 28 2025
NASDAQ.COM
Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata
Oct 21 2025
PRnewswire
Biotech Stocks Soar in After-Hours Trading: PCSA, PALI, and QTTB Top the Charts in Volume and Speculation
Oct 08 2025
NASDAQ.COM
Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference
Aug 28 2025
PRnewswire
Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug 06 2025
PRnewswire
Why Levi Strauss Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
Jul 11 2025
Benzinga
Notable Thursday Option Activity: SLNO, OKTA, QTTB
Jul 10 2025
NASDAQ.COM
Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer
Jun 25 2025
Newsfilter
Show More News
